Brutons Tyrosine Kinase Inhibitor
Dec 10, 2019
Acquisition of ArQule; Synthorx; and Zentalis nabs a raise
Merck is set to complete the already planned purchase of the ArQule for USD 2.7 Billion. Under the terms of the agreement, Merck will pay USD 20 for each share in cash for a total amount of USD 2.7 Billion. ArQule is a biopharmaceutical, which is focused on kinase inhibitor discovery, finding cures for cancer p...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
